1h Free Analyst Time
CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.CSL Ltd Key Recent Developments
- Oct 05, 2022: CSL announces positive preclinical data for self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates
- Aug 10, 2022: CSL launches new unified global brand identity
- Jun 02, 2022: Seqirus' Holly Springs manufacturing facility designated by U.S. Government as pandemic ready
- Feb 07, 2022: Seqirus, a business of CSL, announces new facility supporting research & development of leading-edge influenza vaccine technology
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novo Nordisk AS
- Eli Lilly and Company Ltd
- AstraZeneca Plc
- Alexion Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- GSK plc
- AbbVie Inc
- Vertex Pharmaceuticals Inc
- UCB SA
- Merck KGaA & Co Werk Spittal
- Biogen Inc
- Bausch Health Companies Inc
- Amgen Inc
- Allergan Ltd
- Gilead Sciences Inc
- Grifols SA
- Bayer Aktiengesellschaft Leverkusen
- Bioverativ Inc
- Gilead Sciences Inc
- Bioverativ Inc
- UCB SA
- Merck KGaA & Co Werk Spittal
- Biogen Inc
- Bausch Health Companies Inc
- Amgen Inc
- Novo Nordisk AS
- Eli Lilly and Company Ltd
- AstraZeneca Plc
- Alexion Pharmaceuticals Inc
- Allergan Ltd
- Regeneron Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Grifols SA
- Bayer Aktiengesellschaft Leverkusen
- Vertex Pharmaceuticals Inc
- GSK plc
- AbbVie Inc